Epiminder: Cochlear-backed Aussie innovator raises $16m to test seizure epilepsy monitoring device

Australian medical device innovator Epiminder has raised $16 million to expand its ongoing UMPIRE (sUb-scalp Monitoring ePileptic seIzuREs) clinical trial for Minder®, an ultra-long-term ambulatory electroencephalography (EEG) monitoring device. According to the official announcement, in addition to expanding its UMPIRE clinical trial to multiple clinical sites in Victoria, Queensland and New South Wales, the company will also expand product development, manufacturing and corporate activities.Continue reading Cochlear-backed Aussie innovator raises $16m to test seizure epilepsy monitoring device at Australian Manufacturing.